Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 12, 2023HematologiaOpen Access

Waldenström macroglobulinemia: diagnosis and treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

KGKrzysztof Giannopoulos

Discussion

Loading...

Member takes

Overview

Clinical review highlights diagnostic molecular markers and targeted therapies in Waldenström macroglobulinemia, indicating expanded options for personalized disease management.

Key Points

  • Review the diagnostic criteria, impact of key molecular markers, and current therapeutic strategies for Waldenström macroglobulinemia.
  • Summarized diagnostic definitions based on the 2017 World Health Organization classification combining bone marrow lymphoplasmacytic lymphoma and IgM monoclonal gammopathy.
  • Evaluated the prognostic and therapeutic utility of MYD88 and CXCR4 mutational testing alongside recent targeted therapies.
  • MYD88 and CXCR4 mutational profiles significantly alter clinical presentation and determine therapeutic responsiveness.
  • Treatment selection relies on patient age, neuropathy risk, and susceptibility to secondary malignancies or immunosuppression.
  • Regulatory approvals of BTK inhibitors ibrutinib and zanubrutinib significantly expand targeted management options.

Cite This Study

Krzysztof Giannopoulos (2023) studied this question.

synapsesocial.com/papers/6aa85cdea789130cf6269f4ahttps://doi.org/10.5603/hcp.a2022.0014
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.2024 · 11 citations
  2. 2Clinical Characteristics and Treatment Outcome of Waldenstrom Macroglobulinemia: Experience from a Tertiary Cancer Centre2024 · 1 citations
  3. 3Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience2026
  4. 4Current Approaches in the Management of Monoclonal Gammopathies: an approach to Waldenström Macroglobulinemia2024
  5. 5Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions2026